Objective: To build a clinical risk score to aid risk stratification among hospitalised COVID-19 patients. Methods: The score was built using data of 417 consecutive COVID-19 in patients from Kuwait. Risk factors for COVID-19 mortality were identified by multivariate logistic regressions and assigned weighted points proportional to their beta coefficient values. A final score was obtained for each patient and tested against death to calculate an Receiver-operating characteristic curve. Youden's index was used to determine the cut-off value for death prediction risk. The score was internally validated using another COVID-19 Kuwaiti-patient cohort of 923 patients. External validation was carried out using 178 patients from the Italian CoViDiab cohort. Results: Deceased COVID-19 patients more likely showed glucose levels of 7.0–11.1 mmol/L (34.4%, p < 0.0001) or >11.1 mmol/L (44.3%, p < 0.0001), and comorbidities such as diabetes and hypertension compared to those who survived (39.3% vs. 20.4% [p = 0.0027] and 45.9% vs. 26.6% [p = 0.0036], respectively). The risk factors for in-hospital mortality in the final model were gender, nationality, asthma, and glucose categories (<5.0, 5.5–6.9, 7.0–11.1, or 11.1 > mmol/L). A score of ≥5.5 points predicted death with 75% sensitivity and 86.3% specificity (area under the curve (AUC) 0.901). Internal validation resulted in an AUC of 0.826, and external validation showed an AUC of 0.687. Conclusion: This clinical risk score was built with easy-to-collect data and had good probability of predicting in-hospital death among COVID-19 patients.

Development of a clinical risk score to predict death in patients with COVID-19 / Alhamar, G., Maddaloni, E., Al Shukry, A., Al-Sabah, S., Al-Haddad, M., Al-Youha, S., Jamal, M., Almazeedi, S., Al-Shammari, A.A., Abu-Farha, M., Abubaker, J., Alattar, A.T., Alozairi, E., Alessandri, F., D'Onofrio, L., Leto, G., Mastroianni, C.M., Mignogna, C., Pascarella, G., Pugliese, F., et al.. - In: DIABETES/METABOLISM RESEARCH AND REVIEWS. - ISSN 1520-7552. - 38:5(2022). [10.1002/dmrr.3526]

Development of a clinical risk score to predict death in patients with COVID-19

Maddaloni E.;Alessandri F.;D'Onofrio L.;Leto G.;Mastroianni C. M.;Mignogna C.;Pugliese F.;Buzzetti R.;Pozzilli P.
2022

Abstract

Objective: To build a clinical risk score to aid risk stratification among hospitalised COVID-19 patients. Methods: The score was built using data of 417 consecutive COVID-19 in patients from Kuwait. Risk factors for COVID-19 mortality were identified by multivariate logistic regressions and assigned weighted points proportional to their beta coefficient values. A final score was obtained for each patient and tested against death to calculate an Receiver-operating characteristic curve. Youden's index was used to determine the cut-off value for death prediction risk. The score was internally validated using another COVID-19 Kuwaiti-patient cohort of 923 patients. External validation was carried out using 178 patients from the Italian CoViDiab cohort. Results: Deceased COVID-19 patients more likely showed glucose levels of 7.0–11.1 mmol/L (34.4%, p < 0.0001) or >11.1 mmol/L (44.3%, p < 0.0001), and comorbidities such as diabetes and hypertension compared to those who survived (39.3% vs. 20.4% [p = 0.0027] and 45.9% vs. 26.6% [p = 0.0036], respectively). The risk factors for in-hospital mortality in the final model were gender, nationality, asthma, and glucose categories (<5.0, 5.5–6.9, 7.0–11.1, or 11.1 > mmol/L). A score of ≥5.5 points predicted death with 75% sensitivity and 86.3% specificity (area under the curve (AUC) 0.901). Internal validation resulted in an AUC of 0.826, and external validation showed an AUC of 0.687. Conclusion: This clinical risk score was built with easy-to-collect data and had good probability of predicting in-hospital death among COVID-19 patients.
2022
clinical risk score; comorbidities; covid-19; glucose control; hyperglycemia; intensive care
01 Pubblicazione su rivista::01a Articolo in rivista
Development of a clinical risk score to predict death in patients with COVID-19 / Alhamar, G., Maddaloni, E., Al Shukry, A., Al-Sabah, S., Al-Haddad, M., Al-Youha, S., Jamal, M., Almazeedi, S., Al-Shammari, A.A., Abu-Farha, M., Abubaker, J., Alattar, A.T., Alozairi, E., Alessandri, F., D'Onofrio, L., Leto, G., Mastroianni, C.M., Mignogna, C., Pascarella, G., Pugliese, F., et al.. - In: DIABETES/METABOLISM RESEARCH AND REVIEWS. - ISSN 1520-7552. - 38:5(2022). [10.1002/dmrr.3526]
File allegati a questo prodotto
File Dimensione Formato  
Alhamar_Development_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 235.53 kB
Formato Adobe PDF
235.53 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1630528
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 10
social impact